Pharvaris N.V. $PHVS Shares Purchased by General Atlantic L.P.

General Atlantic L.P. raised its stake in Pharvaris N.V. (NASDAQ:PHVS) by 6.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,031,252 shares of the company’s stock after purchasing an additional 500,000 shares during the period. Pharvaris comprises 6.0% of General Atlantic L.P.’s investment portfolio, making the stock its 8th biggest position. General Atlantic L.P. owned approximately 15.36% of Pharvaris worth $200,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in PHVS. Geode Capital Management LLC grew its position in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after buying an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc lifted its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi grew its holdings in Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares in the last quarter. Finally, HighVista Strategies LLC increased its position in shares of Pharvaris by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after purchasing an additional 971 shares during the last quarter.

Pharvaris Stock Performance

Shares of PHVS opened at $25.42 on Friday. The company’s 50 day simple moving average is $26.69 and its 200-day simple moving average is $24.97. Pharvaris N.V. has a 12-month low of $11.51 and a 12-month high of $29.80.

Analyst Ratings Changes

Several research firms have recently issued reports on PHVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Guggenheim increased their price target on shares of Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Morgan Stanley raised their price objective on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Finally, Bank of America boosted their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Thursday, December 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.70.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.